Treatment of thrombotic thrombocytopenic purpura (TTP) centers on emergency plasma exchange, immunosuppression, and increasingly, targeted therapies that block the runaway blood clotting that defines the disease. A century ago TTP was almost universally fatal; today, survival exceeds 95 percent thanks to a sequence of advances that arrived over decades. Yet the treatment landscape is still evolving, with newer drugs reshaping how quickly patients recover and how reliably they stay in remission.
What Goes Wrong in TTP
TTP is driven by a shortage of a specific enzyme called ADAMTS13, whose job is to trim a large sticky blood protein known as von Willebrand factor (VWF). When ADAMTS13 is missing or blocked, oversized VWF molecules accumulate in small blood vessels and drag platelets into clumps, forming tiny clots throughout the body. The result is a dangerous combination: platelets get used up (causing easy bleeding and bruising), red blood cells get shredded passing through clot-narrowed vessels, and organs like the brain and kidneys can be starved of blood flow.1PubMed Central. ADAMTS13 in the New Era of TTP
In the most common form, immune TTP (iTTP), the patient’s own immune system produces autoantibodies that attack ADAMTS13, driving the enzyme’s activity below 10 percent of normal.2Mediterranean Journal of Hematology and Infectious Diseases. Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis and Open Issues A much rarer inherited form, congenital TTP, results from genetic mutations that leave the body unable to produce functional ADAMTS13 from birth. The two forms share the same downstream problem but require different treatment strategies.
Why Speed of Diagnosis Matters
Untreated iTTP is rapidly fatal, so the decision to begin plasma exchange often has to be made before lab results come back confirming an ADAMTS13 level below 10 percent.3ASH Publications. Medical consult: aHUS, TTP? How to distinguish and what to do Many hospitals cannot run ADAMTS13 assays quickly enough, so clinicians rely on bedside scoring tools such as the PLASMIC score to estimate the likelihood of TTP and justify starting treatment immediately.4PubMed Central. Role of the PLASMIC Score in the Management of Thrombotic Thrombocytopenic Purpura The PLASMIC score pulls together routine lab values and clinical features to generate a probability. A high score means treatment should start right away, even before the definitive enzyme test is available.
One of the main diagnostic challenges is distinguishing iTTP from a related condition called atypical hemolytic uremic syndrome (aHUS), which involves uncontrolled activation of the complement system rather than ADAMTS13 deficiency. Both diseases feature low platelets and shredded red blood cells, but they require different treatments. Delays in sorting out which is which increase the risk of irreversible kidney damage in aHUS and death in iTTP.5ASH Publications. Medical consult: aHUS, TTP? How to distinguish and what to do
Plasma Exchange as the Foundation
Therapeutic plasma exchange (TPE) has been the backbone of TTP treatment since a landmark 1991 Canadian trial showed it was dramatically superior to simple plasma infusions in reducing mortality.6PubMed Central. The history of thrombotic thrombocytopenic purpura research: a narrative review The procedure works on two fronts: it removes the autoantibodies and oversized VWF multimers circulating in the patient’s blood, and it replaces the missing ADAMTS13 via fresh donor plasma. Before plasma exchange became standard, most patients with TTP died within days of diagnosis.7PubMed Central. TTP: From empiricism for an enigmatic disease to targeted molecular therapies
Plasma exchange works well when it can outpace the antibodies. In patients whose ADAMTS13 activity is severely low but who do not have a high-titer inhibitor (a particularly aggressive antibody), serial plasma exchange can lead to complete remission with recovery of ADAMTS13 levels. But patients with high-titer inhibitors pose a tougher problem: in one study, three out of four such patients had recurrent disease or died despite exchange, because the antibodies were being produced faster than they could be removed.8Blood. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura This is the fundamental limitation that drives the need for immunosuppressive drugs alongside exchange.
Corticosteroids as an Early Add-On
Steroids are given to nearly every patient with iTTP from the start, on the logic that they help dampen the immune attack on ADAMTS13. Most providers add corticosteroids up front and continue them through early remission, following international guidelines, in part because the drugs are inexpensive and carry a relatively low risk profile compared to the disease itself.9PubMed Central. The modern role of corticosteroids in immune thrombotic thrombocytopenic purpura A comparative study found that corticosteroids should be used as an adjunct to plasma exchange in all patients being treated for an acute episode of iTTP.10Blood Advances. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura
The honest state of the evidence, though, is less tidy than “give steroids.” There is no consensus on which steroid to use, at what dose, or for how long. Some centers favor high-dose pulses of methylprednisolone, others use oral prednisone tapered over weeks, and the data comparing these approaches head-to-head is thin.11PubMed Central. The modern role of corticosteroids in immune thrombotic thrombocytopenic purpura Corticosteroids clearly help, but exactly how to optimize them remains an open question.
Caplacizumab and Faster Platelet Recovery
Caplacizumab is the first targeted therapy approved specifically for acquired TTP, and it works by a completely different mechanism than plasma exchange or steroids. Instead of suppressing the immune system or removing antibodies, it blocks the interaction between oversized VWF multimers and platelets, essentially preventing the sticky clumps from forming in the first place.12PubMed. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Two randomized trials established its benefit. The earlier phase 2 trial showed that caplacizumab reduced the time to platelet normalization by about 39 percent compared to placebo.13PubMed. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura The larger phase 3 HERCULES trial confirmed this: the median time to normal platelet counts was shorter with caplacizumab (roughly 2.7 days versus 2.9 days), and patients receiving the drug were about one and a half times as likely to achieve platelet normalization at any given time point.14PubMed. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura Beyond the platelet numbers, the drug reduced TTP-related deaths, recurrences during treatment, and the total volume of plasma exchange needed.
There is a trade-off, however. Because caplacizumab blocks VWF from doing its normal clotting job, it creates a drug-induced form of von Willebrand disease. In the HERCULES trial, bleeding events of any kind were more common in the caplacizumab arm (about 65 percent of patients) than in the placebo arm (about 48 percent), though most of these bleeds were minor.15Journal of Thrombosis and Haemostasis. Perspectives on the management of immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era A meta-analysis pooling data from trials and observational studies confirmed a statistically significant increase in bleeding risk with caplacizumab, with about a 40 percent higher relative risk of treatment-related bleeding compared to standard care alone.16PubMed Central. Does Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse exacerbation and bleeding For most patients the trade-off favors using the drug, since the danger of ongoing microclotting far outweighs the risk of minor mucosal bleeding, but the bleeding risk means clinicians need to monitor carefully and sometimes adjust or hold doses.
Rituximab for Relapse Prevention
Even after a successful acute episode, iTTP has a stubborn tendency to relapse. The autoantibodies that caused the first episode can reappear months or years later, and about a third to half of patients eventually relapse without additional immune-targeted treatment. Rituximab, a drug that depletes the B cells responsible for producing those antibodies, has become central to preventing relapses.
Rituximab drives ADAMTS13 activity back into the normal range in a large majority of patients. In one study of 76 treatment episodes, ADAMTS13 fully normalized (to at least 60 percent activity) in about 79 percent of cases, and recovered to at least 30 percent in over 92 percent. Over a median follow-up of 15 months, only three relapses occurred in the group that received a reduced-dose regimen.17Blood Advances. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens This has led many centers to use rituximab preemptively when monitoring shows ADAMTS13 levels starting to fall, rather than waiting for a full clinical relapse.
One of the more striking and troubling findings in TTP research involves racial disparities in rituximab’s effectiveness. A study of iTTP patients in the United States found that rituximab substantially improved relapse-free survival in White patients, roughly doubling the proportion who remained relapse-free at five years compared to corticosteroids alone. In Black patients, however, rituximab did not appear to improve relapse-free survival at all, a difference that was statistically significant.18Blood. Race, rituximab, and relapse in TTP The reasons remain unclear and are likely a mix of biological, immunological, and social factors, but the finding has practical consequences: Black patients with iTTP may need closer monitoring and potentially different long-term strategies, and clinicians should not assume that a course of rituximab provides the same degree of protection it does for other populations.
When Standard Treatment Fails
A small but important fraction of iTTP patients do not respond adequately to plasma exchange, steroids, and rituximab. These refractory cases are among the most dangerous clinical scenarios, because the microclotting continues unabated. In the current treatment era, caplacizumab can buy time by blocking new clot formation, but it does not address the underlying immune cause.
Bortezomib, a drug originally developed for multiple myeloma, has emerged as a salvage option for refractory iTTP. It works by targeting plasma cells, the long-lived antibody factories that rituximab often cannot reach. An Italian multicenter study of 17 patients treated with bortezomib reported responses in about 59 percent overall, with a particularly strong response rate of 82 percent among those treated during the acute phase. The median duration of response was 22 months, and several responses were still ongoing at data cutoff.19Journal of Thrombosis and Haemostasis. Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study Earlier case series had shown similarly encouraging results, with 11 of 12 published patients surviving acute episodes and maintaining remission after bortezomib treatment.20PubMed. Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura
The evidence for bortezomib is still based on small studies rather than large randomized trials, so it remains a second- or third-line option. But for patients running out of alternatives, it represents a genuinely promising avenue.
Treating Congenital TTP
Congenital TTP, caused by inherited mutations rather than autoantibodies, follows a fundamentally different treatment logic. Because the immune system is not the problem, immunosuppressive drugs like rituximab are irrelevant. Instead, the goal is simply to replace the missing ADAMTS13. Historically, this has been done through regular infusions of fresh frozen plasma, either to treat acute flares or on a prophylactic schedule to prevent them.21PubMed Central. A case of congenital TTP presenting with microganiopathy in adulthood
The biggest recent advance for congenital TTP is recombinant ADAMTS13, a lab-manufactured version of the enzyme that no longer requires donor plasma. A clinical trial found that no acute TTP events occurred during prophylaxis with recombinant ADAMTS13, compared to a low but nonzero event rate with standard plasma therapy. Drug-related side effects were dramatically less common with the recombinant product (9 percent versus 48 percent with standard therapy), and no patients needed to stop treatment because of adverse events, compared with eight patients on standard therapy who had to discontinue.22PubMed. Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Recombinant ADAMTS13 gives a purer, more consistent dose of the enzyme and eliminates the risks associated with blood-derived products, making it a meaningful quality-of-life improvement for people who need enzyme replacement for life.
Long-Term Health After Surviving TTP
Surviving an acute TTP episode is not the end of the story. Mounting evidence shows that iTTP survivors carry an increased burden of chronic health problems, including cognitive impairment, higher rates of hypertension and ischemic events like stroke, and elevated rates of anxiety and depression.23PubMed. Relapse and beyond: Navigating the long-term clinical impacts of immune thrombotic thrombocytopenic purpura The cognitive effects can be subtle, things like trouble concentrating, memory difficulties, and brain fog, but they are common enough that many survivors report meaningful impacts on work and daily life.
Whether these long-term effects are caused by the microclotting that occurred during the acute episode, by the treatments themselves, or by ongoing subclinical disease is not fully settled. What is clear is that TTP follow-up should extend well beyond monitoring for relapse. Survivors benefit from screening for cardiovascular risk factors, neuropsychological assessment when cognitive complaints arise, and mental health support. Many TTP specialty centers now run dedicated survivorship clinics for this purpose.
Monitoring ADAMTS13 to Predict Relapse
After an acute episode of iTTP resolves, ADAMTS13 levels are typically checked at regular intervals, because a falling enzyme level often precedes a clinical relapse by weeks or months. This gives clinicians a window to intervene preemptively with rituximab before the patient becomes sick again.
Recent research has refined this monitoring approach further. The shape, or conformation, of the ADAMTS13 molecule at its peak activity level appears to predict how quickly relapse will occur. Patients whose ADAMTS13 was in an “open” conformation at its highest measured level needed preemptive rituximab significantly earlier, at a median of 10 months, compared to 25 months for those with a “closed” conformation.24Blood. Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura If validated more broadly, this kind of testing could help personalize follow-up schedules, giving higher-risk patients more frequent monitoring while sparing lower-risk patients unnecessary clinic visits and rituximab infusions.
The Cost Problem With Caplacizumab
Caplacizumab’s clinical benefits are real but come with a significant price tag, and this has sparked an active debate about value. A cost-effectiveness analysis modeled the addition of caplacizumab to standard care over a five-year period and arrived at a projected cost per quality-adjusted life-year gained of over $1.4 million, far above the commonly accepted willingness-to-pay threshold of roughly $195,000 in the United States. In simulations, standard care without caplacizumab was favored in every single iteration.25PubMed Central. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
The main driver of this unfavorable ratio is the drug’s high cost combined with its failure to reduce long-term relapse rates. Caplacizumab speeds recovery from the acute episode and reduces the number of plasma exchange sessions needed, but once the drug is stopped, the underlying autoimmune process can still reignite. Rituximab and other immunosuppressants are what actually modify the disease course over time. This creates a genuine clinical tension: caplacizumab makes the acute phase safer and shorter, which matters enormously for individual patients, but from a health-system perspective, the dollars-per-outcome math is hard to justify at current pricing.
For patients and clinicians, this often translates into insurance authorization battles and variable access depending on hospital formulary decisions. In some countries with centralized health-technology assessment, reimbursement for caplacizumab has been conditional on specific clinical criteria, restricting its use to the sickest patients or those with markers of high risk. Whether broader competition or future price reductions will shift this calculus remains to be seen.
How Treatment Has Transformed Survival
The arc of TTP treatment over the past century is one of the more dramatic turnarounds in medicine. For over 50 years after the disease was first described in 1924, the majority of patients died within days of diagnosis, and diagnosis was often made only at autopsy.26PubMed Central. TTP: From empiricism for an enigmatic disease to targeted molecular therapies The introduction of plasma exchange in the early 1990s, validated by the Canadian Apheresis Study Group trial, was described by some reviewers as one of the most impactful medical interventions in history for its effect on TTP mortality.27PubMed Central. The history of thrombotic thrombocytopenic purpura research: a narrative review Survival rates have continued climbing with each added layer of treatment, from steroids to rituximab to caplacizumab, and now exceed 95 percent in centers with access to the full range of therapies.28PubMed. Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025
What has not changed, and deserves emphasis, is that TTP remains a medical emergency requiring immediate treatment. The window between presentation and irreversible organ damage is narrow, and the most sophisticated therapies in the world do nothing for a patient whose diagnosis is missed or delayed. The PLASMIC score, rapid ADAMTS13 assays where available, and a high index of clinical suspicion remain as important as any drug in the treatment toolkit.